Growing Concern In Asia Over Resistance To Artemisinin-Based Antimalarial Medicines

“Growing resistance to a key anti-malarial drug derived from a shrub used in traditional Chinese medicine is threatening to roll back gains made in combating the disease,” according to experts attending a U.N.-sponsored malaria conference that concluded on Friday in Sydney, Australia, the U.N. News Centre reports. Malaria “therapies based on artemisinin — an extract from the sweet wormwood bush used for centuries in Chinese medicine as a fever cure — were” formulated in combination with other antimalarials to form artemisinin-based combination therapies (ACTs) that the WHO thought would be effective for years, but resistance to the ACTs has begun to appear in some areas, the news service notes. “Specifically, [the Roll Back Malaria Partnership] noted, artemisinin resistance has been detected in Cambodia, Myanmar, Thailand and Vietnam,” the news service writes (11/2). Agence France-Presse examines efforts to fight drug-resistant malaria on the Thai-Myanmar border (Rook, 11/4).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.